Steris plc

STE

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001757898

B

second fifth of 305 graded peers in healthcare

rank 96 of 305; percentile 31.2; sampling error 2.8 points; lower is stronger

A B C D E

B, the elk



Scoreboard

Profitability	B/C	percentile 40.6
Solvency	C	percentile 46.5
Growth and financing	B/C	percentile 40.2
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $10.7B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: distress
Inputs computable	10 of 13	
Graded from	filings received through May 29, 2026	175 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$254.91	2026-11-19; market equity $24.8B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received May 29, 2026

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.6						
Gross profitability	24.5%	32.8%		58.0	346	2026-03-31
Return on invested capital	not computable	9.6%				
latest aligned inputs end 2021-03-31; latest annual assets end 2026-03-31						
Accruals ratio	(5.4%)	(6.7%)		60.0	756	2026-03-31
Gross margin stability, five years	0.5 pts	2.8 pts		3.8	237	2026-03-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 46.5						
Altman Z double-prime	4.50	0.31		21.0	705	2026-03-31
Net debt to EBITDA	not computable	1.82x				
latest aligned inputs end 2021-03-31; latest annual assets end 2026-03-31						
Interest coverage	not computable	(3.61x)				
latest aligned inputs end 2024-03-31; latest annual assets end 2026-03-31						
Current ratio	2.09x	2.68x		71.9	781	2026-03-31
Growth and financing, sleeve percentile 40.2						
Revenue growth, three-year compound	9.4%	9.6%		51.6	400	2026-03-31
Free cash flow growth, three-year compound	35.0%	11.1%		29.0	94	2026-03-31
Reinvestment rate	18.6%	33.9%		59.0	101	2026-03-31
Asset growth, three years	(0.3%)	3.2%		52.0	663	2026-03-31
Net share issuance, one year	(0.8%)	1.6%		9.3	625	2026-05-27

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
91	Biocryst Pharmaceuticals Inc. (BCRX)	29.6	B	fortress balance sheet
92	MSA Safety Inc. (MSA)	29.9	B	
93	Cadre Holdings, Inc. (CDRE)	30.3	B	
94	Rigel Pharmaceuticals Inc. (RIGL)	30.6	B	
95	Twist Bioscience Corp. (TWST)	30.9	B	fortress balance sheet
96	Steris plc (STE)	31.2	B	
97	BioNexus Gene Lab Corp. (BGLC)	31.6	B	dilution, late filer
98	Sarepta Therapeutics, Inc. (SRPT)	31.9	B	
99	Amphastar Pharmaceuticals, Inc. (AMPH)	32.2	B	
100	Staar Surgical Co. (STAA)	32.6	B	
101	Arcutis Biotherapeutics, Inc. (ARQT)	32.9	B	

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(10.2%)	(1.7%)	43
Distance from 52-week high	(5.2%)	(31.7%)	89
EBIT to enterprise value	4.3%	0.5%	72
Free cash flow yield	3.9%	0.6%	71
Book value to price	0.29	0.29	50
Sales to price	0.24	0.37	36
Composite equity issuance, five years	8.3%	13.5%	43
Relative strength against the sector, log excess return	(0.28)	(0.19)	43
Twelve-month failure probability, CHS model	not computable	0.06%	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 9 of 9, period end 2026-03-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$531.1M
Operating cash flow, four quarters	$1.3B
Months of runway	not finite
Days since last periodic filing	15 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$140.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2.6B	2026-03-31	2026-05-29	10-K	26-039136
2	assets	us-gaap:Assets	$10.7B	2026-03-31	2026-05-29	10-K	26-039136
3	operating income	us-gaap:OperatingIncomeLoss	$548.4M	2021-03-31	2023-05-26	10-K	23-000005
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$517.5M	2021-03-31	2021-05-28	10-K	21-000017
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$120.7M	2021-03-31	2023-05-26	10-K	23-000005
6	total debt	us-gaap:LongTermDebt	$1.7B	2021-03-31	2022-05-31	10-K	22-000011
7	book equity	us-gaap:StockholdersEquity	$3.9B	2021-03-31	2022-05-31	10-K	22-000011
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$220.5M	2021-03-31	2021-05-28	10-K	21-000017
9	total debt	us-gaap:LongTermDebt	$1.2B	2020-03-31	2021-05-28	10-K	21-000017
10	book equity	us-gaap:StockholdersEquity	$3.4B	2020-03-31	2021-05-28	10-K	21-000017
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$319.6M	2020-03-31	2021-05-28	10-K	21-000017
12	net income	us-gaap:NetIncomeLoss	$782.3M	2026-03-31	2026-05-29	10-K	26-039136
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.3B	2026-03-31	2026-05-29	10-K	26-039136
14	assets	us-gaap:Assets	$10.1B	2025-03-31	2026-05-29	10-K	26-039136
15	revenue	us-gaap:Revenues	$5.9B	2026-03-31	2026-05-29	10-K	26-039136
16	gross profit	us-gaap:GrossProfit	$2.4B	2025-03-31	2026-05-29	10-K	26-039136
17	revenue	us-gaap:Revenues	$5.5B	2025-03-31	2026-05-29	10-K	26-039136
18	gross profit	us-gaap:GrossProfit	$2.2B	2024-03-31	2026-05-29	10-K	26-039136
19	revenue	us-gaap:Revenues	$5.1B	2024-03-31	2026-05-29	10-K	26-039136
20	gross profit	us-gaap:GrossProfit	$2.0B	2023-03-31	2025-05-29	10-K	25-000005
21	revenue	us-gaap:Revenues	$4.5B	2023-03-31	2025-05-29	10-K	25-000005
22	gross profit	us-gaap:GrossProfit	$1.9B	2022-03-31	2024-05-29	10-K	24-000008
23	revenue	us-gaap:Revenues	$4.2B	2022-03-31	2024-05-29	10-K	24-000008
24	current assets	us-gaap:AssetsCurrent	$2.4B	2026-03-31	2026-05-29	10-K	26-039136
25	current liabilities	us-gaap:LiabilitiesCurrent	$1.1B	2026-03-31	2026-05-29	10-K	26-039136
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$3.0B	2026-03-31	2026-05-29	10-K	26-039136
27	operating income	us-gaap:OperatingIncomeLoss	$1.1B	2026-03-31	2026-05-29	10-K	26-039136
28	book equity	us-gaap:StockholdersEquity	$7.2B	2026-03-31	2026-05-29	10-K	26-039136
29	liabilities	us-gaap:Liabilities	$3.5B	2026-03-31	2026-05-29	10-K	26-039136
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$219.2M	2021-03-31	2023-05-26	10-K	23-000005
31	operating income	us-gaap:OperatingIncomeLoss	$836.1M	2024-03-31	2026-05-29	10-K	26-039136

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	interest expense	us-gaap:InterestExpense	$144.4M	2024-03-31	2024-05-29	10-K	24-000008
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$369.0M	2026-03-31	2026-05-29	10-K	26-039136
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.1B	2025-03-31	2026-05-29	10-K	26-039136
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$370.1M	2025-03-31	2026-05-29	10-K	26-039136
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$973.3M	2024-03-31	2026-05-29	10-K	26-039136
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$360.3M	2024-03-31	2026-05-29	10-K	26-039136
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$756.9M	2023-03-31	2025-05-29	10-K	25-000005
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$362.0M	2023-03-31	2025-05-29	10-K	25-000005
40	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$486.5M	2026-03-31	2026-05-29	10-K	26-039136
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.0B	2026-03-31	2026-05-29	10-K	26-039136
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$262.2M	2026-03-31	2026-05-29	10-K	26-039136
43	current assets	us-gaap:AssetsCurrent	$2.0B	2025-03-31	2026-05-29	10-K	26-039136
44	current liabilities	us-gaap:LiabilitiesCurrent	$1.0B	2025-03-31	2026-05-29	10-K	26-039136
45	assets	us-gaap:Assets	$11.1B	2024-03-31	2025-05-29	10-K	25-000005
46	assets	us-gaap:Assets	$10.8B	2023-03-31	2024-05-29	10-K	24-000008
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	97,602,485	2026-05-27	2026-05-29	10-K	26-039136
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	98,372,310	2025-05-27	2025-05-29	10-K	25-000005

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.